News Conference News TCT 2019 Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA Michael O'Riordan September 28, 2019
News Daily News Enlarged Left Atria Can ID Patients With ESUS Who May Benefit From a DOAC Todd Neale April 08, 2019
News Daily News Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks Todd Neale August 13, 2018
News Daily News NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin L.A. McKeown May 16, 2018
News Industry News New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment January 29, 2018
News Daily News NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin L.A. McKeown January 02, 2018
News Conference News VIVA 2017 Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients L.A. McKeown September 11, 2017
News Daily News In Case of Emergency: Don’t Rely on ‘Normal’ Range Assays With DOACs Shelley Wood August 10, 2017
News Daily News If You Don’t Take Your Stroke Meds, This App Will Tell on You Todd Neale April 18, 2017
News Conference News ISC 2017 NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin Todd Neale March 01, 2017
News Conference News AHA 2016 Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding Shelley Wood November 21, 2016
News Conference News AHA 2016 Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias Shelley Wood November 21, 2016
News Daily News Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns Shelley Wood September 13, 2016
News Daily News Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas Shelley Wood September 13, 2016
News Conference News ESC 2016 NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry Michael O'Riordan August 28, 2016
News Daily News FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors Michael O'Riordan August 18, 2016
News Daily News Según una Revisión las Evidencias que Avalan la Exclusión Percutánea o Quirúrgica del AAI para la Prevención de ACV son Limitadas Todd Neale July 14, 2016
News Daily News Evidence Supporting Percutaneous or Surgical LAA Exclusion for Stroke Prevention Is Limited, Review Says Todd Neale July 14, 2016
News Daily News Un Estudio del Mundo Real Confirma los Efectos de Apixaban y Rivaroxaban en el Manejo de la FA Todd Neale April 21, 2016